Company founder and the core team have more than 20 years of global experience in drug R&D and commercialization. It has an efficient team driven by innovative technologies and products.
The company is enhancing its pipeline in the focused areas of genitourinary diseases. APL-1202, for the treatment of non-invasive bladder cancer, and APL-1702, for the treatment of precancerous cervical lesion, have entered phase III clinical trials. At the same time, the company has a number of first-in-class drug candidates as well as other innovative medicines with huge unmet medical needs, which are in the R&D and preclinical research stages.
The company works closely with KOLs and medical institutions. It has forged strong partnerships with leading research institutions and pharmaceutical companies.
We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.